Media playback is not supported on this device
The Hoff has been seduced by the Scottish Premiership outfit during a Panto stint in Glasgow.
The former Baywatch and Knight Rider tweeted his support for the side earlier this month.
"They've been around since 1876 and I love that. It's about playing for themselves and playing for your honour," he told BBC Scotland.
Partick Thistle's new mascot Kingsley - designed by Turner Prize-nominated artist David Shrigley - caused a social media storm on its home debut in June.
The yellow character was paraded at Firhill Stadium, but The Hoff insists he is the club's new lucky mascot.
And he drew parallels with the side and one of his acting successes.
"It's like Knight Rider was a show about how one man can make a difference; you can make a difference in your own life and someone else's life," he said.
"That's what the team's about I think.
"We came over here [to Glasgow] and [were] making a joke about the worst team in the history of the world - if they win four games in a row then it's the best record in 40 years.
"There's something strange about that; it's a wonderful thing when you can come over and draw that energy. I am the lucky mascot and I'm proud to be the lucky mascot.
"I'm putting it out in a positive way and I'm the one who did all this. I said, 'let's give reference to Partick Thistle. I didn't know who they are? Let's find them'. We did.
"And that's what we do and I think that's why we've lasted so long and people respond to me. Knight Rider was real for me and when I got it I called my Dad and said, 'Dad, I've got the greatest show in the world'. I'm still living the dream."

The firm is to license a new cancer treatment to Californian company Genentech.
The treatment is a class of drug molecules developed by Almac's discovery division.
Genentech will make an upfront payment of around £9m with further payments and possible royalties to follow.
Almac will be eligible to receive up to £225m in milestone payments plus royalties on commercial sales of any products developed by Genentech
The two companies will also run a two-year joint research programme funded by Genentech
The drug molecules are called inhibitors of ubiquitin specific proteases.
They block the activity of an important cancer pathway which is believed to play a key role in tumour development.
Tim Harrison, vice president of drug discovery at Almac, said they have been "a highly sought after, yet elusive drug class, proving difficult to identify despite significant efforts from both pharmaceutical and biotech companies".
He added that there was now "an exciting opportunity to fully exploit this novel biology".
Genentech was founded in San Francisco in 1976 and is widely considered to be the world's most successful biotechnology company.
It has developed products such as the cancer drug Avastin and the stroke treatment Activase.
In 2009, the Swiss drug company Roche took control of Genentech, paying £30bn for the 44% of the firm it did not own.
Meanwhile, California-based CV6 Therapeutics Ltd is to partner with the Centre for Cancer Research and Cell Biology at Queen's University, Belfast for a research and development project.
The project aims to develop a new drug with the potential to make chemotherapy more effective and represents a total investment of £5.5m.
Invest NI has offered assistance of £2.5m towards the project, which includes part funding from the European Regional Development Fund (ERDF).
American actor David Hasselhoff says he supports Partick Thistle because they are "a team for the people".
[NEXT_CONCEPT]
Craigavon-based pharmaceutical firm Almac has signed a deal with one of the world's largest biotech firms that could be worth more than £200m.